Serving 500+ biopharmaceutical companies globally:
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
Serving 500+ biopharmaceutical companies globally:
Generated: July 23, 2017
What is the patent landscape for Ceftriaxone, and when can generic versions of Ceftriaxone launch?
Ceftriaxone is a drug marketed by Qilu Pharm Co Ltd, Aurobindo Pharma Ltd, Sandoz Inc, Akorn Inc, Lupin, Teva Pharms Usa, Acs Dobfar, Hospira Inc, Hikma Farmaceutica, Fresenius Kabi Usa, Samson Medcl, Teva, Bedford, Agila Speclts, Sandoz, Facta Farma, Wockhardt, Cephazone Pharma, B Braun, Baxter Hlthcare, and Sagent Pharms. and is included in thirty-three NDAs.| Patents: | 0 |
| Applicants: | 21 |
| NDAs: | 33 |
| Suppliers / Packagers: see list | 25 |
| Bulk Api Vendors: see list | 22 |
| Clinical Trials: see list | 107 |
| Patent Applications: see list | 5,040 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | see details |
| DailyMed Link: | CEFTRIAXONE at DailyMed |
| Ingredient-type | Cephalosporins |
| Drug Class | Cephalosporin Antibacterial |
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cephazone Pharma | CEFTRIAXONE | ceftriaxone sodium | INJECTABLE;INTRAMUSCULAR, INTRAVENOUS | 065294-002 | Mar 26, 2007 | DISCN | No | No | ► Subscribe | ► Subscribe | |||||||||||||||||||
Fresenius Kabi Usa | CEFTRIAXONE | ceftriaxone sodium | INJECTABLE;INTRAMUSCULAR, INTRAVENOUS | 065245-001 | Feb 15, 2006 | DISCN | No | No | ► Subscribe | ► Subscribe | |||||||||||||||||||
Hospira Inc | CEFTRIAXONE | ceftriaxone sodium | INJECTABLE;INJECTION | 065231-001 | Aug 2, 2005 | DISCN | No | No | ► Subscribe | ► Subscribe | |||||||||||||||||||
Lupin | CEFTRIAXONE | ceftriaxone sodium | INJECTABLE;INJECTION | 065263-001 | Sep 12, 2006 | AP | RX | No | No | ► Subscribe | ► Subscribe | ||||||||||||||||||
Sandoz | CEFTRIAXONE | ceftriaxone sodium | INJECTABLE;INTRAMUSCULAR, INTRAVENOUS | 065169-004 | May 9, 2005 | AP | RX | No | Yes | ► Subscribe | ► Subscribe | ||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
Serving 500+ biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Follow DrugPatentWatch:
Join the 22,091 other biopharmaceutical professionals who get our Drug Patent Expiration Alerts:
